TKL Research Inc.
Welcome,         Profile    Billing    Logout  
 5 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lu, Ming
NCT05165407: Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC

Recruiting
2
40
RoW
Sintilimab, IBI310, Surufatinib, HMPL-012
Peking University
Neuroendocrine Neoplasm
03/24
03/25
NCT05894486: Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Not yet recruiting
2
40
RoW
Lutetium[177Lu] Oxodotreotide Injection, 177Lu-DOTA0-Tyr3-Octreotate
Peking University
Neuroendocrine Tumors
06/25
06/26
Dosik, Jonathan
CIPT, NCT06369675: Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design

Completed
1
45
US
MOB015B, 0.2% SLS, 0.9% Saline, MOB015B vehicle
Moberg Pharma AB
Erythema
11/17
11/17
Andresen, C
No trials found

Download Options